4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0000950170-23-070416
Senior VP, Chief Pharma Dev. sold 3,800 shares at an average $222.82 ($846,700)
- Senior VP, Chief Pharma Dev. acquired 3,800 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-12 | Option exercise | +1,300 | $87.92 | $114,296 | 6,967 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-12 | Sale | −500 | $216.00 | $108,000 | 6,467 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-12 | Sale | −800 | $219.00 | $175,200 | 5,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-13 | Option exercise | +2,500 | $87.92 | $219,800 | 8,167 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-13 | Sale | −1,500 | $225.00 | $337,500 | 6,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-13 | Sale | −1,000 | $226.00 | $226,000 | 5,667 | D |
| Derivatives | |||||||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-12 | Option exercise · Stock Option (Right to Buy) | −1,300 | 23,700 | D | ||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-13 | Option exercise · Stock Option (Right to Buy) | −2,500 | 21,200 | D | ||
| Open-market sales · 3,800 sh · avg $222.82 · $846,700 | |||||||
Loading xslF345X05/ownership.xml…